Regn stock price continues to attract option traders

REGN stock price continues to attract option traders, with open interest rising 18% in bullish contracts. This positioning suggests the market is bracing for a possible upside surprise from upcoming FDA review decisions. Indeed, you’re covering many bases with a sizeable biotech stock that only seems to get more attractive the longer you hold it. With intriguing catalysts on the horizon and a still modest valuation, I’m inclined to stand with Wall Street with a bullish position on the name. Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months: Technically, REGN stock price faces minor resistance at $945 based on recent swing highs. MACD crossovers hint at potential acceleration if positive clinical developments emerge this quarter.